Key facts
- 3X Genetics’s last known valuation is $14.0M (Mar 2026).
- It has raised $3.2M across 1 recorded rounds; the latest was Seed Round ($3.2M) in Aug 2024.
- Notable investors include Alumni Ventures, Morningside Group, Massachusetts Biomedical Initiatives, Wire Group (Massachusetts).
- 3X Genetics has filed 1 Form D with the SEC, most recently Mar 2026 ($3.2M sold to 52 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for 3X Genetics
Funding rounds
1 roundsAbout 3X Genetics
Developer of medical screening technology designed to proactively identify genetic disorders. The company's technology screens the population for myotonic dystrophy and other trinucleotide repeat issues that cause progressive muscle weakness, enabling healthcare professionals to prevent the birth of children with genetic diseases.
- Sector
- Healthcare
- HQ
- Worcester, MA, United States
- Founded
- 2021
- Employees
- 10
- Website
- 3xgenetics.com/
- Ownership
- Privately Held (backing)
3X Genetics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 3X Genetics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 3X Genetics in its N-PORT filings yet. We sweep new filings monthly.